- Home
- BGLC vs BDRX Comparison
BGLC vs BDRX Comparison
Compare BGLC & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- BDRX
- Stock Information
- Founded
- BGLC 2017
- BDRX 2000
- Country
- BGLC Malaysia
- BDRX United Kingdom
- Employees
- BGLC N/A
- BDRX N/A
- Industry
- BGLC Medical Specialities
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- BDRX Health Care
- Exchange
- BGLC Nasdaq
- BDRX Nasdaq
- Market Cap
- BGLC 10.7M
- BDRX 5.8M
- IPO Year
- BGLC N/A
- BDRX N/A
- Fundamental
- Price
- BGLC $5.09
- BDRX $0.87
- Analyst Decision
- BGLC
- BDRX
- Analyst Count
- BGLC 0
- BDRX 0
- Target Price
- BGLC N/A
- BDRX N/A
- AVG Volume (30 Days)
- BGLC 2.7M
- BDRX 3.1M
- Earning Date
- BGLC 08-13-2025
- BDRX 04-11-2025
- Dividend Yield
- BGLC N/A
- BDRX N/A
- EPS Growth
- BGLC N/A
- BDRX N/A
- EPS
- BGLC N/A
- BDRX N/A
- Revenue
- BGLC $9,265,870.00
- BDRX N/A
- Revenue This Year
- BGLC N/A
- BDRX N/A
- Revenue Next Year
- BGLC N/A
- BDRX N/A
- P/E Ratio
- BGLC N/A
- BDRX N/A
- Revenue Growth
- BGLC N/A
- BDRX N/A
- 52 Week Low
- BGLC $2.01
- BDRX $0.78
- 52 Week High
- BGLC $15.60
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- BGLC 52.61
- BDRX 38.67
- Support Level
- BGLC $5.33
- BDRX $0.85
- Resistance Level
- BGLC $6.39
- BDRX $0.92
- Average True Range (ATR)
- BGLC 1.18
- BDRX 0.06
- MACD
- BGLC 0.10
- BDRX 0.01
- Stochastic Oscillator
- BGLC 19.15
- BDRX 32.73
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.